314 related articles for article (PubMed ID: 35925819)
1. Searching for Novel Anaplastic Lymphoma Kinase Inhibitors: Structure-Guided Screening of Natural Compounds for a Tyrosine Kinase Therapeutic Target in Cancers.
Adnan M; Koli S; Mohammad T; Siddiqui AJ; Patel M; Alshammari N; Bardakci F; Elasbali AM; Hassan MI
OMICS; 2022 Aug; 26(8):461-470. PubMed ID: 35925819
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Potent ALK Inhibitors Using Pharmacophore-Informatics Strategy.
James N; Ramanathan K
Cell Biochem Biophys; 2018 Jun; 76(1-2):111-124. PubMed ID: 28477056
[TBL] [Abstract][Full Text] [Related]
3. Anaplastic lymphoma kinase as a therapeutic target in anaplastic large cell lymphoma, non-small cell lung cancer and neuroblastoma.
Cheng M; Ott GR
Anticancer Agents Med Chem; 2010 Mar; 10(3):236-49. PubMed ID: 20406193
[TBL] [Abstract][Full Text] [Related]
4. A Computer - Aided Drug Designing for Pharmacological Inhibition of Mutant ALK for the Treatment of Non-small Cell Lung Cancer.
Sharda S; Khandelwal R; Adhikary R; Sharma D; Majhi M; Hussain T; Nayarisseri A; Singh SK
Curr Top Med Chem; 2019; 19(13):1129-1144. PubMed ID: 31109278
[TBL] [Abstract][Full Text] [Related]
5. An updated patent review of anaplastic lymphoma kinase inhibitors (2018-2022).
Ma D; Guo M; Zhai X
Expert Opin Ther Pat; 2023 Apr; 33(4):323-337. PubMed ID: 37208827
[TBL] [Abstract][Full Text] [Related]
6. CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.
Cheng M; Quail MR; Gingrich DE; Ott GR; Lu L; Wan W; Albom MS; Angeles TS; Aimone LD; Cristofani F; Machiorlatti R; Abele C; Ator MA; Dorsey BD; Inghirami G; Ruggeri BA
Mol Cancer Ther; 2012 Mar; 11(3):670-9. PubMed ID: 22203728
[TBL] [Abstract][Full Text] [Related]
7. Density Functional Theory and Molecular Simulation Studies for Prioritizing Anaplastic Lymphoma Kinase Inhibitors.
James N; Shanthi V; Ramanathan K
Appl Biochem Biotechnol; 2020 Apr; 190(4):1127-1146. PubMed ID: 31712989
[TBL] [Abstract][Full Text] [Related]
8. Drug Design for ALK-Positive NSCLC: an Integrated Pharmacophore-Based 3D QSAR and Virtual Screening Strategy.
James N; Shanthi V; Ramanathan K
Appl Biochem Biotechnol; 2018 May; 185(1):289-315. PubMed ID: 29134510
[TBL] [Abstract][Full Text] [Related]
9. Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK).
Zhang C; Han XR; Yang X; Jiang B; Liu J; Xiong Y; Jin J
Eur J Med Chem; 2018 May; 151():304-314. PubMed ID: 29627725
[TBL] [Abstract][Full Text] [Related]
10. Recent Updates on Structural Aspects of ALK Inhibitors as an Anticancer Agent.
Ayaz MS; Bhupal R; Sharma P; Sahu A; Singh P; Gupta GD; Asati V
Anticancer Agents Med Chem; 2023; 23(8):900-921. PubMed ID: 36627781
[TBL] [Abstract][Full Text] [Related]
11. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.
McDermott U; Iafrate AJ; Gray NS; Shioda T; Classon M; Maheswaran S; Zhou W; Choi HG; Smith SL; Dowell L; Ulkus LE; Kuhlmann G; Greninger P; Christensen JG; Haber DA; Settleman J
Cancer Res; 2008 May; 68(9):3389-95. PubMed ID: 18451166
[TBL] [Abstract][Full Text] [Related]
12. New perspectives for targeting therapy in ALK-positive human cancers.
Zhao S; Li J; Xia Q; Liu K; Dong Z
Oncogene; 2023 Jun; 42(24):1959-1969. PubMed ID: 37149665
[TBL] [Abstract][Full Text] [Related]
13. The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice.
Mori M; Ueno Y; Konagai S; Fushiki H; Shimada I; Kondoh Y; Saito R; Mori K; Shindou N; Soga T; Sakagami H; Furutani T; Doihara H; Kudoh M; Kuromitsu S
Mol Cancer Ther; 2014 Feb; 13(2):329-40. PubMed ID: 24419060
[TBL] [Abstract][Full Text] [Related]
14. Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK).
Kong X; Pan P; Sun H; Xia H; Wang X; Li Y; Hou T
J Med Chem; 2019 Dec; 62(24):10927-10954. PubMed ID: 31419130
[TBL] [Abstract][Full Text] [Related]
15. Virtual screening and further development of novel ALK inhibitors.
Okamoto M; Kojima H; Saito N; Okabe T; Masuda Y; Furuya T; Nagano T
Bioorg Med Chem; 2011 May; 19(10):3086-95. PubMed ID: 21515061
[TBL] [Abstract][Full Text] [Related]
16. ALK inhibitors in the treatment of advanced NSCLC.
Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
[TBL] [Abstract][Full Text] [Related]
17. Identification of novel anaplastic lymphoma kinase (ALK) inhibitors using a common feature pharmacophore model derived from known ligands crystallized with ALK.
Xie HZ; Lan H; Pan YL; Zou J; Wang ZR; Li LL; Huang Q; Zhang H; Yang SY
Chem Biol Drug Des; 2013 Feb; 81(2):175-84. PubMed ID: 23107363
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.
Katayama R; Lovly CM; Shaw AT
Clin Cancer Res; 2015 May; 21(10):2227-35. PubMed ID: 25979929
[TBL] [Abstract][Full Text] [Related]
19. Recent Development in the Discovery of Anaplastic Lymphoma Kinase (ALK) Inhibitors for Non-small Cell Lung Cancer.
Liu J; Ma S
Curr Med Chem; 2017; 24(6):590-613. PubMed ID: 27804873
[TBL] [Abstract][Full Text] [Related]
20. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
Sgambato A; Casaluce F; Maione P; Gridelli C
Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]